Drug Profile
Recombinant erythropoietin biosimilar - Axxo
Latest Information Update: 26 Sep 2013
Price :
$50
*
At a glance
- Originator AXXO
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Chemotherapy-induced anaemia
Most Recent Events
- 17 Sep 2013 Investigation for Chemotherapy-induced anaemia in Germany (Parenteral)